Glimepiride strongly enhances the glucose-lowering effect in triple oral antidiabetes therapy with sitagliptin and metformin for Japanese patients with type 2 diabetes mellitus

Diabetes Technology and Therapeutics

Volumn 15, Issue 4, 2013, Pages 335-341

  Arai, Keiko ^a,b   Maeda, Hajime ^b   Sirabe, Sin Ichiro ^b   Yamamoto, Ritsuko ^b   Yamauchi, Mikio ^b   Hirao, Tetsuyuki ^b   Hirao, Setsuko ^b   Hirao, Koichi ^b  

^a Arai Clinic   (Japan)

^b Health Education Center Science Clinic   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GLIMEPIRIDE; GLUCOSE; HEMOGLOBIN A1C; METFORMIN; SITAGLIPTIN;

ADULT; AGED; ANTIDIABETIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG MEGADOSE; DRUG POTENTIATION; DRUG WITHDRAWAL; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; JAPANESE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; POLYPHARMACY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

AGED; AGED, 80 AND OVER; BLOOD GLUCOSE; BODY MASS INDEX; C-PEPTIDE; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; JAPAN; MALE; METFORMIN; MIDDLE AGED; PROSPECTIVE STUDIES; PYRAZINES; SULFONYLUREA COMPOUNDS; TREATMENT OUTCOME; TRIAZOLES;

EID: 84876143593     PISSN: 15209156     EISSN: 15578593     Source Type: Journal    
DOI: 10.1089/dia.2012.0287     Document Type: Article

References (26)

1. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR: Management of hyperglycemia in type 2 diabetes: A patientcentered approach: Position statement of American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35:1364-1379.
2. Araki E, Yasuhiko I, Kadowaki T, Kashiwagi A, Kitaoka M, Nanjyo K, Tajima N: Oral drug treatment. In: Japan Diabetes Society (ed.). Treatment Guide for Diabetes 2007. Tokyo: Bunkodo, 2007:42-46.
3. Dagog-Jack S. Ethnic disparities in type 2 diabetes: Pathophysiology and implication for prevention and management. J Natl Med Assoc 2003;95:774, 779-789.
4. Arai K, Matoba K, Hirao K, Matsuba I, Takai M, Takeda H, Kanamori A, Yamauchi M, Mori H, Terauchi Y: Present status of sulfonylurea treatment for type 2 diabetes in Japan: Second report of a cross-sectional survey of 15,652 patients. Endocr J 2010;57:499-507.
5. Aschner P, Kinpes MS, Lunceford JK, Sanchez M, Michael C, Williams-Herman DE: Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 2006;29:2632-2637.
6. Charbonnel B, Karasik A, Liu J, Wu M, Meininger G: Efficiency and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 2006; 29:2638-2643.
7. Goldstein BJ, Johnson J, Feinglos MN, Williams-Herman DE, Lunceford JK; Sitagliptin 036 Study Group: Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care 2007;30:1979-1987.
8. Hermansen K, Kipnes M, Luo E, Fanurik D, Khatami H, Stein P; Sitagliptin 035 Study Group: Efficiency and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metab 2007;9:737-745.
9. Maeda H, Kubota A, Tanaka Y, Terauchi Y, Matsuba I; ASSET-K Study Group: The safety, efficiency and predictors for HbA1c reduction of sitagliptin in the treatment of Japanese type 2 diabetes. Diabetes Res Clin Pract 2012;95:e20- e22.
10. Chong, HS, Lee MK: Efficiency of sitagliptin when added to ongoing therapy in Korean subjects with type 2 diabetes mellitus. Diabetes Metab J 2011;35:411-417.
11. Hirao K, Maeda H, Shirabe S, Yamamoto R, Hirao T, Hirao S, Yamauchi M, Arai K: Combination therapy with a dipeptidyl peptidase-4 inhibitor, sulfonylurea, and metformin markedly improves HbA1c levels in Japanese patients with type 2 diabetes mellitus. Jpn Clin Med 2012;3:1-7.
12. Kuzuya T, Nakagawa S, Satoh J, Kanazawa Y, Iwamoto Y, Kobayashi T, Nanjo K, Sakai A, Seino Y, Ito C, Shima K, Nonaka K, Kadowaki T; Committee of the Japan Diabetes Society on the Diagnostic Criteria of Diabetes Mellitus: Report of the Committee on the Classification and Diagnostic Criteria of Diabetes Mellitus. Diabetes Res Clin Pract 2002;55:65-85.
13. Alberti KG, Zimmet PZ: Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes provisional report of a WHO consultation. Diabet Med 1998;15:539-553.
14. Seino Y, Nanjo K, Tajima N, Kadowaki T, Kashiwagi A, Araki E, Ito C, Inagaki N, Iwamoto Y, Kasuga M, Hanafusa T, Haneda M, Ueki K: Report of the Committee on the Classification and Diagnostic Criteria of Diabetes Mellitus. Diabetol Int 2010;1:2-20.
15. Goto A, Takaichi M, Kishimoto M, Takahshi Y, Kajio H, Shimbo T, Noda M: Body mass index, fasting plasma glucose levels, and C-peptide levels as predictors of the future insulin use in Japanese type 2 diabetic patients. Endocr J 2010;57:237-244.
16. Saisho Y, Kou K, Tanaka K, Abe T, Kurosawa T, Shimada A, Meguro S, Kawai T, Itoh H: Postprandial serum C-peptide to plasma glucose ratio as a predictor of subsequent insulin treatment in patients with type 2 diabetes. Endocr J 2011; 58:315-322.
17. Turner RC, Holman RR, Mathew D, Hockday TD, Peto J: Insulin deficiency and insulin resistance interaction in diabetes - estimation of their relative contribution by feedback analysis from basal insulin and glucose concentration. Metabolism 1979;28:1086-1096.
18. Mathews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-419.
19. Maida A, Lamont BJ, Cao X, Drucker DJ: Metformin regulates the incretin receptor axis via a pathway dependent on peroxisome proliferators-activated receptor-a in mice. Diabetologia 2011;54:339-349.
20. Migoya EM, Bergeron R, Miller JL, Synder RNK, Tanen M, Hilliard D, Weiss B, Larson P, Gutierrez M, Jiang G, Liu F, Pryor KA, Yao J, Zhu L, Holst JJ, Deacon C, Herman G, Thornberry N, Amatruda J, Williams-Herman D, Wagner JA, ShinhaRoy R: Dipeptidyl peptidase-4 inhibitors administered in combination with metformin results in an additive increase in the plasma concentration of active GLP-1. Clin Pharmacol Ther 2010;88:801-808.
21. Urakaze M, Yamazaki K, Usui I, Iwata M, Uno T, Murakami A, Yamamoto U, Kishida M, Aikawa H, Kawahara J, Senda S, Ishizuka K, Ikemoto M, Sawazaki S, Fukui K, Takano A, Yamazaki Y, Hori H, Wada O, Kamura Y, Igarashi Y, Sato A, Fukushima H, Takata M, Temaru R, Ohgaku S, Akagawa N, Kato H, Kobayashi M: Glimepiride (0.5 mg/day) administration improves glycemic control without weight gain in Japanese type 2 diabetic patients. J Jpn Diabetes Soc 2007; 50:835-841.
22. Report of drug event monitoring [in Japanese]. J Jpn Pharm Assoc 2011;63:1259-1272.
23. Zhang CL, Katoh M, Shibasaki T, Minami K, Sunaga Y, Takahashi H, Yokoi N, Iwasaki M, Miki T, Seino S: The cAMP sensor Epac2 is a direct target of antidiabetic sulfonylurea drugs. Science 2009;325:607-610.
24. Shibasaki T, Takahashi H, Miki T, Sunaga Y, Matsumura K, Yamanaka M, Zhang CL, Tamamoto A, Satoh T, Miyazaki J, Seino S: Essential role of Epac2/Rap 1 signaling in regulation of insulin granule dynamics by cAMP. Proc Natl Acad Sci U S A 2007;104:19333-19338.
25. Miki T, Nagashima K, Tashiro F, Kotake K, Yoshitomi H, Tamamoto A, Gonoi T, Iwanaga T, Miyazaki J, Seino S: Defective insulin secretion and enhanced insulin action in KATP channel-deficient mice. Proc Natl Acad Sci U S A 1998;95:10402-10406.
26. Harashima S-I, Ogura M, Tanaka D, Fukusima T, Wang Y, Koizumi T, Aono M, Murata Y, Seike M, Inagaki N: Sitagliptin add-on to low dosage sulfonylureas: Efficiency and safety of combination therapy on glycemic control and insulin secretion capacity in type 2 diabetes. Int J Clin Pract 2012;65:465-476.